Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Female Reproductive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm
Female Reproductive System Neoplasm

Subtype

Female Reproductive System Neoplasm

CI-CAN-00000885Explore in graph →

Non-malignant1,629 active trials11 approved drugs139 evidence items

NCIt: C3053
MeSH: D005833

Overview
Statistics
Survival
Genomics36
Variants & evidence139
Drugs44
Trials7170
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (324)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 301–324 of 324 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
· Clin Cancer Res · 2011 · PMID 22016507 · validated civic_curation pubmed
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
· Oncotarget · 2016 · PMID 27489350 · validated civic_curation pubmed
Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.
· Oncol Rep · 2012 · PMID 22246397 · validated civic_curation pubmed
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
· Int J Cancer · 2009 · PMID 19533750 · validated civic_curation pubmed
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
· Nat Commun · 2025 · PMID 40169546 · validated civic_curation pubmed
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
· PLoS One · 2014 · PMID 24927325 · validated civic_curation pubmed
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
· Mol Cancer Ther · 2006 · PMID 17088436 · validated civic_curation

Showing 301–324 of 324 publications

← Previous
1
…
12
13
Next →

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

· Gynecol Oncol · 2005 · PMID 15790433 · validated civic_curation pubmed

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.

· Oncotarget · 2015 · PMID 26204491 · validated civic_curation pubmed

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

· Mol Oncol · 2013 · PMID 23415752 · validated civic_curation pubmed

Elkin et al. NPJ Genome Med 2021

· 2021 · PMID 34819508 · validated cbioportal_study pubmed

Manning-Geist et al. Clin Cancer Res. 2022

· 2022 · PMID 35443055 · validated cbioportal_study pubmed

TCGA, Nature 2011

· 2011 · PMID 21720365 · validated cbioportal_study pubmed

Le Gallo et al. Cancer 2017

· 2017 · PMID 28485815 · validated cbioportal_study pubmed

Weigelt et al. Cancer Discovery 2023

· 2023 · PMID 37651310 · validated cbioportal_study pubmed

Ashley et al. Clin Cancer Res 2023

· 2023 · PMID 36007103 · validated cbioportal_study pubmed

· PMID 35849120 · validated cbioportal_study pubmed

Yongchao Dou et al. 2020 Cell.

· 2020 · PMID 32059776 · validated cbioportal_study pubmed

Soumerai et al. Clin Cancer Res. 2018

· 2018 · PMID 30068706 · validated cbioportal_study pubmed

TCGA, Nature 2013

· 2013 · PMID 23636398 · validated cbioportal_study pubmed

Jones et al. Nat Commun 2014

· 2014 · PMID 25233892 · validated cbioportal_study pubmed

Brodeur, Melica Nourmoussavi et al. Molecular oncology 2024

· 2024 · PMID 39031567 · validated cbioportal_study pubmed

Hensley et al. Clin Cancer Res 2020

· 2020 · PMID 32299819 · validated cbioportal_study pubmed

Han et al. Exp Mol Med 2018

· 2018 · PMID 29422544 · validated cbioportal_study pubmed